# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian epithelial cancer

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 525 results.
Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer
Status: Not yet recruiting
Last Changed: Mar 21, 2019
First Received: Jul 18, 2017
Disease(s): Ovarian Epithelial Cancer
Intervention(s): Cytoreductive surgery combined with HIPEC, Chemotherapy and bevacizumab (CT-BEV)
Locations: Centre Hospitalier Lyon Sud, Pierre-Bénite, France
Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer
Status: Recruiting
Last Changed: Oct 15, 2018
First Received: Mar 13, 2017
Disease(s): Ovarian Epithelial Cancer
Intervention(s): SPL-108
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Columbia University Medical Center, New York, New York, United States
Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
Status: Recruiting
Last Changed: Mar 28, 2019
First Received: Jun 20, 2011
Disease(s): Ovarian Epithelial Cancer Recurrent
Intervention(s): Maximal cytoreductive surgery, HIPEC
Locations: Institut Jules Bordet, Brussels, Belgium
CHU d'AMIENS, Amiens, France
Centre Paul Papin, Angers, France
Institut Bergonie, Bordeaux, France
Clinique Pasteur, Brest, France
... and 29 other locations.
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Status: Recruiting
Last Changed: Jul 23, 2019
First Received: Jul 23, 2019
Disease(s): Ovarian Epithelial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Intervention(s): Gimatecan 0.6mg/m2/d, 0.8mg/m2/d, 0.4mg/m2/d
Locations: Beijing Tumor Hospital, Beijing, Beijing, China
NeoVax With Nivolumab in Patients With Ovarian Cancer
Status: Not yet recruiting
Last Changed: Jul 18, 2019
First Received: Jul 18, 2019
Disease(s): Ovarian Cancer
Intervention(s): Nivolumab, NeoVax, Core Needle Biopsy
Locations: Dana Farber Cancer Institute, Boston, Massachusetts, United States
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Status: Recruiting
Last Changed: Nov 14, 2018
First Received: Apr 08, 2014
Disease(s): Ovarian Neoplasms, Ovarian Epithelial Cancer
Intervention(s): DCVAC/OvCa with Standard of Care, DCVAC/OvCa sequentially chemotherapy, Standard of Care
Locations: Brno, Czechia
Brno, Czechia
Hradec Králové, Czechia
Jihlava, Czechia
Nový Jičín, Czechia
... and 16 other locations.
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
Status: Recruiting
Last Changed: Oct 16, 2018
First Received: May 22, 2018
Disease(s): Ovarian Cancer
Intervention(s): Enoxaparin, Enoxaparin + Rosuvastatin, Thromboprophylaxis
Locations: Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
Status: Recruiting
Last Changed: Apr 23, 2019
First Received: Apr 23, 2019
Disease(s): Ovarian Cancer
Intervention(s): Anlotinib
Locations: The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Platino-resistance in Ovarian Cancer
Status: Not yet recruiting
Last Changed: May 17, 2019
First Received: May 17, 2019
Disease(s): Epithelial Ovarian Cancer
Intervention(s): Patients treated with platinum based-chemotherapy
Locations: Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer
Status: Recruiting
Last Changed: Oct 18, 2018
First Received: Jul 04, 2016
Disease(s): Ovarian Epithelial Cancer
Intervention(s): Olaparib, carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
Locations: UZLeuven, Leuven, Belgium